M&A Financial Due Diligence

Overview

Provides a structured framework for financial due diligence in bank M&A transactions, covering earnings quality assessment, balance sheet fair value adjustments, accretion/dilution analysis, cost and revenue synergy validation, pro-forma capital and liquidity impact, and deal pricing evaluation. Designed for deal committee presentations, board approval packages, and regulatory application support (OCC/FDIC/Fed merger applications).

When to Use

Evaluating a potential bank or financial institution acquisition target
Building or reviewing accretion/dilution models for proposed transactions
Assessing fair value marks on target loan portfolios, securities, and deposits
Validating cost and revenue synergy assumptions
Preparing financial analysis sections of regulatory merger applications
Presenting deal economics to board of directors or deal committee

Required Inputs

| Input | Description | Format | |-------|-------------|--------| | Target financials | 3-5 years of income statement, balance sheet, regulatory filings | Call reports / 10-K/Q | | Acquirer financials | Same period financial statements for the acquiring institution | Financial statements | | Target loan tape | Loan-level data (balances, rates, maturities, grades, collateral) | Loan detail extract | | Securities portfolio | CUSIP-level holdings with book value, market value, duration | Investment detail | | Deposit composition | Account-level or product-level deposit data with rates and maturities | Deposit detail | | Deal terms | Purchase price, consideration mix (cash/stock), exchange ratio | Term sheet | | Synergy assumptions | Cost savings by category, revenue synergies, timing | Management estimates | | Market data | Comparable transaction multiples, trading multiples | M&A comps data |

Methodology

Step 1 — Assess Target Earnings Quality

Evaluate the sustainability and quality of the target's reported earnings:

NII quality:

Decompose NIM into asset yield, cost of funds, and free-funds contribution
Identify non-recurring interest income (accretion from prior deals, penalty income, one-time items)
Assess the proportion of NII from purchase accounting accretion on prior acquisitions (declining asset)
Evaluate the loan portfolio yield relative to current origination rates (above-market = roll-off risk)

Fee income quality:

Separate recurring fees (service charges, wealth management) from volatile income (trading, gain on sale)
Identify fee income dependent on the rate environment (mortgage banking volumes)
Assess customer retention risk for fee-generating relationships

Expense normalization:

Identify one-time costs (restructuring, litigation settlements, deal costs from prior M&A)
Normalize compensation for above/below-market levels or unfunded pension obligations
Assess technology and infrastructure spend: underinvestment creating future catch-up requirements

Core earnings run-rate: Adjusted net income after removing non-recurring items, representing sustainable earnings power.

Step 2 — Mark the Balance Sheet to Fair Value

Estimate fair value adjustments (purchase accounting marks) on major balance sheet categories:

Loan portfolio mark:

Apply credit mark: Estimate remaining lifetime losses above the existing allowance using loan-level analysis (PD × LGD × EAD) and stress-adjusted scenarios
Apply rate mark: Discount contractual cash flows at current market rates — below-market fixed-rate loans receive a negative mark, above-market a positive mark
Segment by loan type (CRE, C&I, resi mortgage, consumer) and apply distinct discount rates and loss assumptions
Total loan mark = Credit mark + Rate mark (typically a net negative in rising-rate environments)

Securities mark:

Mark all AFS and HTM securities to current market value
HTM securities often carry significant unrealized losses in rising-rate environments — these crystallize in a purchase
Apply haircuts for illiquid or structured securities

Deposit intangible (CDI):

Core deposit intangible reflects the value of the below-market-rate deposit franchise
Calculate as: PV of the cost savings from paying deposit rates below wholesale funding rates over the expected life of the deposit base
Typical valuation: 1-3% of core deposits, amortized over 7-10 years
Apply deposit decay assumptions based on historical attrition rates

Other fair value adjustments:

Fixed assets: Appraisal vs. book value
Trust preferred or subordinated debt: Mark to current market spreads
Lease obligations: Fair value adjustment for above/below-market leases
Contingent liabilities: Legal, regulatory, environmental exposures

Step 3 — Build the Accretion/Dilution Model

Compute the EPS impact of the transaction on the acquirer:

Key model components:

Target's contribution: Core earnings run-rate (from Step 1)
Purchase accounting adjustments: Amortization of loan mark (accretive as discount accretes into income), amortization of CDI (reduces income), amortization of securities mark
Cost synergies: Phased-in expense reductions (typically 25-35% of target's non-interest expense)
Revenue synergies: Cross-sell, de novo revenue (apply significant haircut — typically 50% of management estimate)
Funding cost impact: Any change in the combined entity's funding cost
Share dilution: Additional shares issued in stock transactions
Financing cost: Interest expense on debt financing for cash transactions

Accretion/dilution calculation: Pro-forma EPS = (Acquirer Earnings + Target Core Earnings + Synergies + PA Adjustments − Financing Costs) / Pro-forma Shares A/D = (Pro-forma EPS − Standalone Acquirer EPS) / Standalone Acquirer EPS

Model over a 5-year horizon showing crossover from dilutive to accretive (if applicable).

Step 4 — Assess Pro-Forma Capital and Liquidity Impact

Evaluate regulatory capital and liquidity impact of the combination:

Capital impact:

Goodwill creation: Purchase price − Target's fair-value-adjusted net assets = Goodwill
Goodwill is deducted from CET1 capital (significant negative impact)
Pro-forma CET1 ratio: (Combined CET1 − Goodwill) / Combined RWA
Assess whether the combined entity requires a capital raise to maintain target ratios
Model capital trajectory under internal capital generation assumptions

Liquidity impact:

Combined LCR and NSFR with pro-forma adjustments
Assess target's funding profile stability (concentration risk, brokered deposits, FHLB reliance)
Evaluate incremental borrowing capacity at FHLB and the discount window
Model pro-forma deposit concentration and diversification benefits

Step 5 — Validate Synergy Assumptions

Critically assess the achievability of projected synergies:

Cost synergies (higher confidence):

Branch overlap: Map branch networks, identify overlapping markets, estimate closable branches × average branch cost
Back-office consolidation: Technology platform migration, operations centers, shared services
Compensation: Eliminate duplicate senior management, overlapping roles
Vendor rationalization: Consolidate contracts at better pricing
Apply realistic phase-in: 25% Year 1, 75% Year 2, 100% Year 3
One-time restructuring costs: Typically 150-200% of annual synergies

Revenue synergies (lower confidence):

Cross-sell: Target's customer base × acquirer's superior product set × take-up rate
Apply significant haircut (50-75%) to management revenue synergy estimates
Revenue synergies typically take 2-3 years to materialize and have high execution risk
Never model revenue synergies as the primary economic justification for a deal

Step 6 — Evaluate Deal Pricing

Assess whether the price represents fair value:

Valuation multiples:

Price / Tangible Book Value (P/TBV): Compare to precedent transactions and trading multiples
Price / Core Earnings (P/E): Based on normalized core earnings, not GAAP
Core deposit premium: (Purchase Price − Target TBV) / Core Deposits
Premium to market: % above target's current trading price (for public targets)

Breakeven analysis:

Cost synergies required for break-even accretion (what percentage of target opex must be eliminated?)
Tangible book value earnback period: Years for acquirer's TBV per share to recover to pre-deal level through retained earnings
IRR of the investment: Discount rate at which NPV of target's future cash flows equals purchase price

Step 7 — Compile the Due Diligence Assessment

Structure the output as a comprehensive deal assessment:

Transaction summary: Price, structure, strategic rationale
Earnings quality: Normalized core earnings and sustainability assessment
Fair value marks: Balance sheet adjustments with total goodwill estimation
Accretion/dilution: 5-year EPS trajectory with crossover point
Capital and liquidity impact: Pro-forma ratios and trajectory
Synergy assessment: Validated cost and revenue synergies with confidence levels
Pricing evaluation: Multiples comparison and breakeven analysis
Key risks: Deal-specific risks and mitigants
Recommendation: Proceed / Renegotiate / Decline with supporting rationale

Output Specification

# M&A Financial Due Diligence — [Target Name]

## Transaction Summary
- Purchase price: $[X]M ([Y]x P/TBV, [Z]x P/E)
- Consideration: [% cash / % stock]
- Core deposit premium: [X]%
- Strategic rationale: [Brief statement]

## Earnings Quality Assessment
| Metric | Reported | Adjustments | Core Run-Rate |
|--------|----------|-------------|---------------|
| NII | | | |
| Fee Income | | | |
| Expenses | | | |
| Provisions | | | |
| Net Income | | | |

## Fair Value Marks ($M)
| Category | Book Value | Fair Value | Mark | Key Assumptions |
|----------|-----------|-----------|------|-----------------|
| Loan portfolio | | | | |
| Securities | | | | |
| CDI | n/a | | | |
| Fixed assets | | | | |
| Deposits (premium) | | | | |
| **Net adjustments** | | | **[Total]** | |
| **Goodwill** | | | **[Total]** | |

## Accretion/Dilution Summary
| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|------------|--------|--------|--------|--------|--------|
| EPS Impact | | | | | |
| A/D % | | | | | |

## Pro-Forma Capital & Liquidity
| Metric | Acquirer | Pro-Forma | Target | Impact |
|--------|----------|-----------|--------|--------|
| CET1 | | | ≥[X]% | |
| Leverage | | | ≥[Y]% | |
| LCR | | | ≥100% | |

## Synergy Assessment
| Category | Mgmt Estimate ($M) | Validated ($M) | Confidence | Phase-in |
|----------|--------------------|--------------------|------------|----------|

## Pricing Evaluation
| Multiple | This Deal | Precedent Median | Premium/(Discount) |
|----------|-----------|------------------|--------------------|

TBV Earnback: [X] years | Deal IRR: [Y]%

## Key Risks
1. [Risk with probability and mitigation]

## Recommendation
[Proceed / Renegotiate / Decline with rationale]

Analysis Framework

Apply the Three Tests of Deal Value:

Strategic test: Does the target fill a genuine strategic gap (geography, capability, scale)?
Financial test: Is the transaction accretive within 2 years with realistic (not aspirational) synergies?
Execution test: Can the integration be executed without disrupting either institution's operations or customers?

A deal should pass all three tests before receiving a positive recommendation. Financial attractiveness alone does not justify execution risk.

Examples

Example — Accretion/Dilution Summary: "At the proposed price of 1.65x TBV ($342M), the transaction is 3.2% dilutive to EPS in Year 1 primarily due to CDI amortization and restructuring charges. With validated cost synergies of $28M (32% of target non-interest expense), the deal crosses to accretive in Q3 of Year 2, reaching 4.8% accretive by Year 3. TBV per share declines from $28.42 to $26.15 at close, with an earnback period of 3.4 years through retained earnings and synergy realization."

Example — Fair Value Mark Narrative: "The loan portfolio carries a net negative mark of $67M (3.8% of book value), comprising a $42M credit mark reflecting estimated additional lifetime losses in the CRE portfolio above existing reserves, and a $25M rate mark on $480M of fixed-rate residential mortgages originated at 3.25% average coupon. The credit mark is driven by 12 classified CRE relationships totaling $184M with updated appraisals showing LTVs of 85-110%. The rate mark accretes into income over the portfolio's 6.2-year weighted average life."

Guidelines

Always normalize target earnings before applying valuation multiples
Apply independent credit judgment on the loan portfolio — do not rely solely on target's internal grades
Model accretion/dilution over 5 years, not just Year 1
Haircut revenue synergies by at least 50% from management estimates
Include one-time restructuring costs in accretion/dilution (not just run-rate synergies)
Assess pro-forma capital impact including full goodwill deduction from CET1
Compare deal pricing to both precedent transactions and current trading multiples
Never justify a deal primarily on revenue synergies — cost synergies must independently support the price

Validation Checklist

[ ] Target earnings normalized for non-recurring items with clear adjustments documented
[ ] Loan portfolio mark reflects both credit and rate components
[ ] CDI valuation uses appropriate deposit decay and discount rate assumptions
[ ] Goodwill calculated as purchase price minus fair-value-adjusted net assets
[ ] Accretion/dilution model includes PA amortization, synergies, restructuring, and financing costs
[ ] Pro-forma CET1 ratio computed with full goodwill deduction
[ ] Cost synergies benchmarked against comparable transactions (25-35% of target OpEx)
[ ] Revenue synergies haircut by ≥50% from management estimates
[ ] Deal multiples compared to precedent transactions and current trading multiples
[ ] TBV earnback period and deal IRR calculated and assessed against thresholds